Owen J. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Owen J. Chen has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Isabelle Gamache
Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Québec, Canada
27 shared publications- Jose Teodoro Junior
Affiliations Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, Québec, Canada, Department of Biochemistry, McGill University, Montréal, Québec, Canada, Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada
27 shared publications - Bruno Gagnon
Department of Family Medicine and Emergency Medicine, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada
19 shared publications Harvey Smith
19 shared publicationsIpshita Nandi
19 shared publicationsJieyi Yang
19 shared publications
Latest Publications
- Open Access
Viral inhibition of the anaphase promoting complex enhances replication by elevating nucleotide pools
The anaphase promoting complex/cyclosome (APC/C) is a large, ubiquitin ligase and a central regulator of cell cycle progression. By targeting key substrates for degradation during mitosis and G1 phase, the APC/C coordinates metabolic fluctuations that occur during the cell cycle. A diverse range of viruses have convergently evolved mechanisms to bind and inhibit the APC/C; however, a molecular understanding for these interactions has never been demonstrated. Here, we use chicken anemia virus (CAV), a small single-stranded DNA virus encoding only three proteins, to demonstrate the importance of viral APC/C inhibition during replication. We show that the Vp3 protein of CAV inhibits the APC/C, causing a dramatic mitotic arrest during infection. Mutant virus lacking Vp3 are defective for replication and can be rescued by APC/C inhibition. Metabolomic profiling during CAV infection revealed that Vp3 expression mediates a broad increase in nucleotide pools. Moreover, viral inhibition of the APC/C resulted in stabilization of enzymes required for nucleotide biosynthesis. These findings suggest that the APC/C is a general target of many viruses to elevate nucleotide levels and facilitate viral genome replication. Author Summary: Viruses dramatically reshape the cells they infect in order to replicate. To do this efficiently, many viruses disrupt the host’s normal control systems, particularly those that regulate cell growth and division. One such system is the anaphase promoting complex/cyclosome (APC/C), a key cellular machine that controls when specific proteins are broken down during the cell cycle. Surprisingly, a wide range of viruses—including adenovirus, HIV, human papillomavirus, herpesvirus, and others—have been shown to interfere with the APC/C. Until now, however, it was unclear why so many unrelated viruses target this same pathway. In our study, we used chicken anemia virus (CAV), one of the smallest known animal viruses, as a simple model to uncover the underlying mechanism. CAV produces just three proteins, one of which—called VP3—strongly inhibits the APC/C. We found that this inhibition increases the availability of nucleotides, the basic building blocks needed to copy viral DNA. By disrupting normal cell cycle control, the virus effectively redirects cellular resources toward its own replication. These findings reveal APC/C inhibition as a common and powerful strategy used by diverse viruses, offering new insight into how viruses exploit host cells and highlighting potential targets for future antiviral therapies.
Open AccessViral inhibition of the anaphase promoting complex enhances replication by elevating nucleotide pools
The anaphase promoting complex/cyclosome (APC/C) is a large, ubiquitin ligase and a central regulator of cell cycle progression. By targeting key substrates for degradation during mitosis and G1 phase, the APC/C coordinates metabolic fluctuations that occur during the cell cycle. A diverse range of viruses have convergently evolved mechanisms to bind and inhibit the APC/C; however, a molecular understanding for these interactions has never been demonstrated. Here, we use chicken anemia virus (CAV), a small single-stranded DNA virus encoding only three proteins, to demonstrate the importance of viral APC/C inhibition during replication. We show that the Vp3 protein of CAV inhibits the APC/C, causing a dramatic mitotic arrest during infection. Mutant virus lacking Vp3 are defective for replication and can be rescued by APC/C inhibition. Metabolomic profiling during CAV infection revealed that Vp3 expression mediates a broad increase in nucleotide pools. Moreover, viral inhibition of the APC/C resulted in stabilization of enzymes required for nucleotide biosynthesis. These findings suggest that the APC/C is a general target of many viruses to elevate nucleotide levels and facilitate viral genome replication. Author Summary: Viruses dramatically reshape the cells they infect in order to replicate. To do this efficiently, many viruses disrupt the host’s normal control systems, particularly those that regulate cell growth and division. One such system is the anaphase promoting complex/cyclosome (APC/C), a key cellular machine that controls when specific proteins are broken down during the cell cycle. Surprisingly, a wide range of viruses—including adenovirus, HIV, human papillomavirus, herpesvirus, and others—have been shown to interfere with the APC/C. Until now, however, it was unclear why so many unrelated viruses target this same pathway. In our study, we used chicken anemia virus (CAV), one of the smallest known animal viruses, as a simple model to uncover the underlying mechanism. CAV produces just three proteins, one of which—called VP3—strongly inhibits the APC/C. We found that this inhibition increases the availability of nucleotides, the basic building blocks needed to copy viral DNA. By disrupting normal cell cycle control, the virus effectively redirects cellular resources toward its own replication. These findings reveal APC/C inhibition as a common and powerful strategy used by diverse viruses, offering new insight into how viruses exploit host cells and highlighting potential targets for future antiviral therapies.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
PTEN loss-of-function contributes to hyperactivation of the PI3K pathway and to drug resistance in breast cancer. Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity. Several studies have suggested that vacuolar (H+)–ATPase (V–ATPase) complex activity is regulated by PI3K signaling. In this study, we showed that loss of PTEN elevated V–ATPase activity. Enhanced V–ATPase activity was mediated by increased expression of the ATPase H+ transporting accessory protein 2 (ATP6AP2), also known as the prorenin receptor (PRR). PRR is cleaved into a secreted extracellular fragment (sPRR) and an intracellular fragment (M8.9) that remains associated with the V–ATPase complex. Reduced PTEN expression increased V–ATPase complex activity in a PRR-dependent manner. Breast cancer cell lines with reduced PTEN expression demonstrated increased PRR expression. Similarly, PRR expression became elevated upon PTEN deletion in a mouse model of breast cancer. Interestingly, concentration of sPRR was elevated in the plasma of patients with breast cancer and correlated with tumor burden in HER2-enriched cancers. Moreover, PRR was essential for proper HER2 receptor expression, localization, and signaling. PRR knockdown attenuated HER2 signaling and resulted in reduced Akt and ERK 1/2 phosphorylation, and in lower mTORC1 activity. Overall, our study demonstrates a mechanism by which PTEN loss in breast cancer can potentiate multiple signaling pathways through upregulation of the V–ATPase complex.Implications:Our study contributed to the understanding of the role of the V–ATPase complex in breast cancer cell tumorigenesis and provided a potential biomarker in breast cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
PTEN loss-of-function contributes to hyperactivation of the PI3K pathway and to drug resistance in breast cancer. Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity. Several studies have suggested that vacuolar (H+)–ATPase (V–ATPase) complex activity is regulated by PI3K signaling. In this study, we showed that loss of PTEN elevated V–ATPase activity. Enhanced V–ATPase activity was mediated by increased expression of the ATPase H+ transporting accessory protein 2 (ATP6AP2), also known as the prorenin receptor (PRR). PRR is cleaved into a secreted extracellular fragment (sPRR) and an intracellular fragment (M8.9) that remains associated with the V–ATPase complex. Reduced PTEN expression increased V–ATPase complex activity in a PRR-dependent manner. Breast cancer cell lines with reduced PTEN expression demonstrated increased PRR expression. Similarly, PRR expression became elevated upon PTEN deletion in a mouse model of breast cancer. Interestingly, concentration of sPRR was elevated in the plasma of patients with breast cancer and correlated with tumor burden in HER2-enriched cancers. Moreover, PRR was essential for proper HER2 receptor expression, localization, and signaling. PRR knockdown attenuated HER2 signaling and resulted in reduced Akt and ERK 1/2 phosphorylation, and in lower mTORC1 activity. Overall, our study demonstrates a mechanism by which PTEN loss in breast cancer can potentiate multiple signaling pathways through upregulation of the V–ATPase complex.Implications:Our study contributed to the understanding of the role of the V–ATPase complex in breast cancer cell tumorigenesis and provided a potential biomarker in breast cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 A from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Clinical parameters of patients from whom tissue microarrays were acquired for PRR staining.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 A from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Clinical parameters of patients from whom tissue microarrays were acquired for PRR staining.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure Legends 1-3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Figure S1. This figure compares ATP6AP2 expression in normal and tumour human prostate and breast tissues. Figure S2. This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells. Figure S3. This figure contains clinical data that complement the observations made in Figure 4.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure Legends 1-3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Figure S1. This figure compares ATP6AP2 expression in normal and tumour human prostate and breast tissues. Figure S2. This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells. Figure S3. This figure contains clinical data that complement the observations made in Figure 4.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Sequence of qPCR, siRNA, and shRNA used
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Sequence of qPCR, siRNA, and shRNA used
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 B from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Clinical parameters of patients from whom tissue microarrays were acquired for P-Akt staining
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 B from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
Clinical parameters of patients from whom tissue microarrays were acquired for P-Akt staining
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure contains clinical data that complement the observations made in Figure 4.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure contains clinical data that complement the observations made in Figure 4.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
PTEN loss-of-function contributes to hyperactivation of the PI3K pathway and to drug resistance in breast cancer. Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity. Several studies have suggested that vacuolar (H+)–ATPase (V–ATPase) complex activity is regulated by PI3K signaling. In this study, we showed that loss of PTEN elevated V–ATPase activity. Enhanced V–ATPase activity was mediated by increased expression of the ATPase H+ transporting accessory protein 2 (ATP6AP2), also known as the prorenin receptor (PRR). PRR is cleaved into a secreted extracellular fragment (sPRR) and an intracellular fragment (M8.9) that remains associated with the V–ATPase complex. Reduced PTEN expression increased V–ATPase complex activity in a PRR-dependent manner. Breast cancer cell lines with reduced PTEN expression demonstrated increased PRR expression. Similarly, PRR expression became elevated upon PTEN deletion in a mouse model of breast cancer. Interestingly, concentration of sPRR was elevated in the plasma of patients with breast cancer and correlated with tumor burden in HER2-enriched cancers. Moreover, PRR was essential for proper HER2 receptor expression, localization, and signaling. PRR knockdown attenuated HER2 signaling and resulted in reduced Akt and ERK 1/2 phosphorylation, and in lower mTORC1 activity. Overall, our study demonstrates a mechanism by which PTEN loss in breast cancer can potentiate multiple signaling pathways through upregulation of the V–ATPase complex.Implications:Our study contributed to the understanding of the role of the V–ATPase complex in breast cancer cell tumorigenesis and provided a potential biomarker in breast cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
PTEN loss-of-function contributes to hyperactivation of the PI3K pathway and to drug resistance in breast cancer. Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity. Several studies have suggested that vacuolar (H+)–ATPase (V–ATPase) complex activity is regulated by PI3K signaling. In this study, we showed that loss of PTEN elevated V–ATPase activity. Enhanced V–ATPase activity was mediated by increased expression of the ATPase H+ transporting accessory protein 2 (ATP6AP2), also known as the prorenin receptor (PRR). PRR is cleaved into a secreted extracellular fragment (sPRR) and an intracellular fragment (M8.9) that remains associated with the V–ATPase complex. Reduced PTEN expression increased V–ATPase complex activity in a PRR-dependent manner. Breast cancer cell lines with reduced PTEN expression demonstrated increased PRR expression. Similarly, PRR expression became elevated upon PTEN deletion in a mouse model of breast cancer. Interestingly, concentration of sPRR was elevated in the plasma of patients with breast cancer and correlated with tumor burden in HER2-enriched cancers. Moreover, PRR was essential for proper HER2 receptor expression, localization, and signaling. PRR knockdown attenuated HER2 signaling and resulted in reduced Akt and ERK 1/2 phosphorylation, and in lower mTORC1 activity. Overall, our study demonstrates a mechanism by which PTEN loss in breast cancer can potentiate multiple signaling pathways through upregulation of the V–ATPase complex.Implications:Our study contributed to the understanding of the role of the V–ATPase complex in breast cancer cell tumorigenesis and provided a potential biomarker in breast cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure compares ATP6AP2 expression in normal and tumour human prostate and breast tissues.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer
This figure compares ATP6AP2 expression in normal and tumour human prostate and breast tissues.